Literature DB >> 22452291

Validity of intraoperative gross examination of myometrial invasion in patients with endometrial cancer: a meta-analysis.

Ioannis D Mavromatis1, Constantine N Antonopoulos, Ioannis L Matsoukis, Constantinos C Frangos, Alkistis Skalkidou, George Creatsas, Eleni Th Petridou.   

Abstract

OBJECTIVE: The current recommended endometrial cancer surgical treatment is abdominal extrafascial total hysterectomy with bilateral salpingo-oophorectomy followed by pelvic lymphadenectomy if >50% myometrial invasion is estimated by intraoperative gross examination (IGE). This meta-analysis aims to quantify evidence regarding the validity/predictive value of IGE staging compared with final histology.
DESIGN: Meta-analysis of studies published until October 2011.
SETTING: Systematic search, according to PRISMA guidelines, of the six major medical literature databases - Medline, Scopus, EMBASE, Google Scholar, Ovid, Cochrane. POPULATION: Sixteen eligible studies including 2567 endometrial cancer patients.
METHODS: Pooled sensitivity/specificity, accuracy, negative/positive predictive value (NPV/PPV) and diagnostic odds ratio (DOR) of IGE were calculated and the summary receiver operator characteristic (sROC) curve was constructed. A meta-regression analysis was used to explore the role of potential modifiers of sensitivity and specificity. MAIN OUTCOME MEASURES: Pooled diagnostic measures of IGE indices. Results. Sixteen studies (15 retrospective, one prospective) meeting the inclusion criteria were qualitatively analyzed. Pooled IGE estimates were: sensitivity = 0.75 (95%CI: 0.72-0.78), specificity = 0.92 (95%CI 0.90-0.94), accuracy = 0.87 (95%CI 0.86-0.88), NPV = 0.89 (95%CI 0.87-0.92), PPV = 0.80 (95%CI 0.76-0.84) and DOR = 36.9 (95%CI 28.7-47.4). No significant modifiers were identified for sensitivity or specificity.
CONCLUSIONS: The synthesized measures presented here for the first time showed that accuracy, sensitivity and specificity of IGE were 87, 75 and 92%, respectively, which indicates that IGE is useful for estimating depth of myometrial invasion and staging of endometrial cancer in clinical practice. The degree to which the relatively low values of some of its performance indicators could be improved remains to be elucidated in order for the values to be comparable with those from frozen section biopsies.
© 2012 The Authors Acta Obstetricia et Gynecologica Scandinavica© 2012 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Mesh:

Year:  2012        PMID: 22452291     DOI: 10.1111/j.1600-0412.2012.01406.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  5 in total

Review 1.  Practical issues related to uterine pathology: staging, frozen section, artifacts, and Lynch syndrome.

Authors:  Robert A Soslow
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

2.  Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion.

Authors:  Christine H Kim; Fady Khoury-Collado; Emma L Barber; Robert A Soslow; Vicky Makker; Mario M Leitao; Yukio Sonoda; Kaled M Alektiar; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2013-10-04       Impact factor: 5.482

3.  Predicting Factors for Pelvic Lymph Node Metastasis in Patients with Apparently Early-Stage Endometrial Cancer.

Authors:  Pariyed Gumtorntip; Yenrudee Poomtavorn; Chamnan Tanprasertkul
Journal:  Asian Pac J Cancer Prev       Date:  2022-02-01

4.  Management of early stage, high-risk endometrial carcinoma: preoperative and surgical considerations.

Authors:  Sareena Singh; Shandhini Raidoo; Gaetan Pettigrew; Robert Debernardo
Journal:  Obstet Gynecol Int       Date:  2013-06-25

5.  Is routine frozen section analysis necessary in patients with non-endometrioid cancer or grade 3 endometrioid cancer?

Authors:  Qingyong Guo; Huan Yi; Xiaodan Chen; Jianrong Song; Lingsi Chen; Xiangqin Zheng
Journal:  Int J Gynaecol Obstet       Date:  2021-05-12       Impact factor: 4.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.